Herein, we report a lung adenocarcinoma patient harboring a rare <i>EGFR</i> E709_T710delinsD mutation who was treated with afatinib as the first-line therapy and achieved a progression-free survival of 23 months. Here, EGFR is linked to lung adenocarcinoma.